PTC Therapeutics (PTCT) News Today $46.73 -1.64 (-3.39%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$47.88 +1.15 (+2.45%) As of 07:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Wellington Management Group LLP Sells 3,105,676 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Wellington Management Group LLP lessened its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 39.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,787,123 shares of the biopharApril 4 at 4:34 AM | marketbeat.comVanguard Group Inc. Buys 53,688 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Vanguard Group Inc. lifted its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 0.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,178,822 shares of the biopharApril 4 at 3:30 AM | marketbeat.comTrexquant Investment LP Purchases 95,418 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Trexquant Investment LP raised its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 43.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 313,417 shares of the biopharmaceutical company's stock after purchApril 3 at 6:16 AM | marketbeat.comKLP Kapitalforvaltning AS Invests $646,000 in PTC Therapeutics, Inc. (NASDAQ:PTCT)KLP Kapitalforvaltning AS bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 14,300 shares of the biopharmaceutical company's stock, valuedApril 3 at 3:42 AM | marketbeat.comThrivent Financial for Lutherans Sells 18,759 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Thrivent Financial for Lutherans trimmed its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 48.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,339 shares of the bioApril 3 at 3:25 AM | marketbeat.comJPMorgan Chase & Co. Lowers PTC Therapeutics (NASDAQ:PTCT) Price Target to $75.00April 2 at 1:55 AM | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Trading Down 8.8% Following Analyst DowngradePTC Therapeutics (NASDAQ:PTCT) Trading Down 8.8% After Analyst DowngradeApril 1 at 2:00 PM | marketbeat.comJPMorgan Chase & Co. Issues Pessimistic Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock PriceJPMorgan Chase & Co. reduced their target price on shares of PTC Therapeutics from $78.00 to $75.00 and set an "overweight" rating for the company in a research report on Monday.April 1 at 10:56 AM | marketbeat.comPictet Asset Management Holding SA Acquires 381,319 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Pictet Asset Management Holding SA boosted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 107.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 736,388 shares of the biopApril 1 at 4:46 AM | marketbeat.com48,728 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Bought by Raymond James Financial Inc.Raymond James Financial Inc. acquired a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 48,728 shares of the biopharmaceutiMarch 31, 2025 | marketbeat.comPTC Therapeutics: European Commission Decides To Adopt CHMP Negative Opinion On TranslarnaMarch 30, 2025 | nasdaq.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 28, 2025 | prnewswire.comPTC Therapeutics says European Commission will remove muscle disorder drugMarch 28, 2025 | reuters.comPTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in EuropeMarch 28, 2025 | prnewswire.comNatixis Advisors LLC Makes New $544,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)Natixis Advisors LLC purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,060 shares of the biopharmaceMarch 28, 2025 | marketbeat.comFirst Week of May 16th Options Trading For PTC TherapeuticsMarch 26, 2025 | nasdaq.comCibc World Markets Corp Invests $322,000 in PTC Therapeutics, Inc. (NASDAQ:PTCT)Cibc World Markets Corp purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 7,127 shares of the biopharmaceutical company's stock, valued at approximately $322,00March 25, 2025 | marketbeat.comProficio Capital Partners LLC Takes $758,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Proficio Capital Partners LLC purchased a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 16,792 shares of the biopharmaceutical companyMarch 23, 2025 | marketbeat.comSector Gamma AS Takes $2.95 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Sector Gamma AS purchased a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 65,250 shares of the biopharmaceutical company's stMarch 22, 2025 | marketbeat.comPTC Therapeutics' New Data Shows Meaningful Benefit Of Sepiapterin In Phenylketonuria PatientsMarch 22, 2025 | nasdaq.comPTC Therapeutics (NASDAQ:PTCT) Sets New 12-Month High - Here's What HappenedPTC Therapeutics (NASDAQ:PTCT) Reaches New 52-Week High - Here's What HappenedMarch 21, 2025 | marketbeat.comPTC Therapeutics presents new data from Phase 3 APHENITY trialMarch 21, 2025 | markets.businessinsider.comConnor Clark & Lunn Investment Management Ltd. Cuts Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Connor Clark & Lunn Investment Management Ltd. decreased its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 39.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 23,632 shares of the biopharmaceutical company's stock after selMarch 21, 2025 | marketbeat.comAlphaQuest LLC Sells 21,277 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)AlphaQuest LLC decreased its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 95.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,082 shares of the biopharmaceutical company's stock aftMarch 21, 2025 | marketbeat.comPTC Therapeutics Presents New Sepiapterin Data from Ongoing StudiesMarch 20, 2025 | prnewswire.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Sells 5,000 Shares of StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) Director Stephanie Okey sold 5,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $54.00, for a total transaction of $270,000.00. Following the completion of the transaction, the director now directly owns 8,867 shares in the company, valued at approximately $478,818. This represents a 36.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.March 18, 2025 | marketbeat.comStephanie Okey Sells 5,000 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) StockMarch 18, 2025 | insidertrades.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. reduced its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 3.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 685,709 shares of the biopMarch 17, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 15,521 SharesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) VP Mark Elliott Boulding sold 15,521 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $53.30, for a total transaction of $827,269.30. Following the completion of the sale, the vice president now owns 103,901 shares in the company, valued at $5,537,923.30. The trade was a 13.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.March 15, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month High on Analyst UpgradePTC Therapeutics (NASDAQ:PTCT) Sets New 1-Year High on Analyst UpgradeMarch 15, 2025 | marketbeat.comJPMorgan Chase & Co. Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock PriceJPMorgan Chase & Co. lifted their price target on PTC Therapeutics from $72.00 to $78.00 and gave the stock an "overweight" rating in a research note on Friday.March 15, 2025 | marketbeat.comJPMorgan ups PTC Therapeutics target, adds to Focus ListMarch 14, 2025 | markets.businessinsider.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of "Moderate Buy" by BrokeragesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has been given an average rating of "Moderate Buy" by the fifteen brokerages that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, four have given a hold recommMarch 14, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Upgraded by Bank of America to "Neutral" RatingBank of America upgraded shares of PTC Therapeutics from an "underperform" rating to a "neutral" rating and upped their price objective for the stock from $41.00 to $55.00 in a research report on Tuesday.March 12, 2025 | marketbeat.comGC Wealth Management RIA LLC Purchases Shares of 8,032 PTC Therapeutics, Inc. (NASDAQ:PTCT)GC Wealth Management RIA LLC purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 8,032 shares of the biopharmaceutical company's stock, valued atMarch 12, 2025 | marketbeat.comB of A Securities Upgrades PTC Therapeutics (PTCT)March 11, 2025 | msn.comSPX Gestao de Recursos Ltda Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)SPX Gestao de Recursos Ltda bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 25,000 shares of the biopharmaceutical company's stock, valued at approximately $1,128,000. Other large inveMarch 11, 2025 | marketbeat.comProficio Capital Partners LLC Acquires Shares of 16,792 PTC Therapeutics, Inc. (NASDAQ:PTCT)Proficio Capital Partners LLC acquired a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 16,792 shares of the biopharmaceutical coMarch 9, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Receives Overweight Rating from Morgan StanleyMorgan Stanley reaffirmed an "overweight" rating and issued a $70.00 price target (up from $67.00) on shares of PTC Therapeutics in a research note on Friday.March 8, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Coverage Initiated at ScotiabankScotiabank started coverage on PTC Therapeutics in a report on Friday. They set a "sector perform" rating and a $55.00 price objective on the stock.March 8, 2025 | marketbeat.comCandriam S.C.A. Decreases Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Candriam S.C.A. reduced its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 4.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 160,109 shares of the biopharmaceutical company's stMarch 8, 2025 | marketbeat.comAigen Investment Management LP Purchases New Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)Aigen Investment Management LP purchased a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 8,896 shares of the biMarch 8, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Director Sells $63,369.60 in StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) Director Allan Steven Jacobson sold 1,230 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $51.52, for a total value of $63,369.60. Following the completion of the sale, the director now directly owns 19,118 shares in the company, valued at approximately $984,959.36. The trade was a 6.04 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.March 7, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Director Allan Steven Jacobson Sells 1,230 SharesMarch 7, 2025 | insidertrades.comCantor Fitzgerald Analysts Boost Earnings Estimates for PTCTPTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for PTC Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now anticipates thatMarch 7, 2025 | marketbeat.comQ1 Earnings Estimate for PTCT Issued By William BlairPTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of PTC Therapeutics in a research report issued to clients and investors on Friday, February 28th. William Blair analyst S. Corwin forecasts that theMarch 3, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Just Reported Annual Earnings And Analysts Are Lifting Their EstimatesMarch 2, 2025 | finance.yahoo.comPTC Therapeutics (NASDAQ:PTCT) Hits New 1-Year High - Here's WhyPTC Therapeutics (NASDAQ:PTCT) Hits New 52-Week High - Here's What HappenedMarch 2, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Shares Gap Down After Analyst DowngradePTC Therapeutics (NASDAQ:PTCT) Shares Gap Down Following Analyst DowngradeMarch 1, 2025 | marketbeat.comJPMorgan Chase & Co. Lowers PTC Therapeutics (NASDAQ:PTCT) Price Target to $72.00JPMorgan Chase & Co. dropped their price target on PTC Therapeutics from $74.00 to $72.00 and set an "overweight" rating for the company in a research report on Friday.March 1, 2025 | marketbeat.com Remove Ads Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Media Mentions By Week PTCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTCT News Sentiment▼0.650.61▲Average Medical News Sentiment PTCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTCT Articles This Week▼156▲PTCT Articles Average Week Remove Ads Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SMMT News ITCI News GMAB News RDY News MRNA News VTRS News ASND News QGEN News ROIV News LNTH News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTCT) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTCT Stock Free PTCT Stock Alerts